Health & Fitness
Health and Fitness
Health and Fitness
Mon, June 27, 2011
Sat, June 25, 2011
Fri, June 24, 2011 Acorda Therapeutics Wins Two 2011 Stevie Awards at the 9th Annual American Business Awards
HAWTHORNE, N.Y.--([ BUSINESS WIRE ])--Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Ron Cohen, M.D., President and CEO of Acorda Therapeutics, was awarded the 2011 Stevie Award for Executive of the Year in the Health Products & Services category at the 9th Annual American Business Awards (ABA) ceremony held on June 20, 2011. Acorda also received the Stevie Award for best Web Site in the Web Site and Blog/Pharmaceuticals category.
"Wea™re thrilled that Acorda was honored by the Stevie Awards this year"
aWea™re thrilled that Acorda was honored by the Stevie Awards this year,a said Ron Cohen. aIn particular, wea™re gratified to have been recognized for our corporate website. We created the site to reflect the passion of the people who work at Acorda and their dedication to its mission of restoring function to people with neurological disabilities. We have received wonderful feedback on the site from patients, their families, health care providers and business colleagues, and we are grateful for the wider recognition bestowed by this Stevie Award.a
The Stevie Awards are given by the ABA to honor and generate public recognition of the achievements and positive contributions of organizations and business people worldwide. To access a full list of 2011 Stevie Award winners and to learn more about the awards, visit [ www.stevieawards.com ].
About [ Acorda Therapeutics ]
Acorda Therapeutics is a biotechnology company developing therapies for multiple sclerosis, spinal cord injury and related nervous system disorders. The Company is commercializing and marketing [ AMPYRA® (dalfampridine ]) Extended Release Tablets, 10 mg, in the United States. AMPYRA is a potassium channel blocker approved as a treatment to improve walking in patients with multiple sclerosis (MS); this was demonstrated by an improvement in walking speed. AMPYRA was developed using Elana™s Matrix Drug Absorption System (MXDAS®) technology and is manufactured by Elan based on a supply agreement with Acorda.
Acorda also markets [ ZANAFLEX CAPSULES® (tizanidine hydrochloride) ], a short-acting drug for the management of spasticity. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Ampyra in the United States and to successfully market Zanaflex Capsules; third party payors (including governmental agencies) may not reimburse for the use of Ampyra at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of Ampyra; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of Ampyra outside of the United States and our dependence on our collaboration partner Biogen Idec in connection therewith; competition; failure to protect Acorda Therapeutics' intellectual property or to defend against the intellectual property claims of others; the ability to obtain additional financing to support Acorda Therapeutics' operations; and, unfavorable results from our preclinical programs. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this release are made only as of the date hereof, and Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.
